Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study

Journal of Clinical Oncology

Volumn 33, Issue 23, 2015, Pages 2516-2522

  Casulo, Carla ^a   Byrtek, Michelle ^c   Dawson, Keith L ^c   Zhou, Xiaolei ^d   Farber, Charles M ^e   Flowers, Christopher R ^f   Hainsworth, John D ^g   Maurer, Matthew J ^h   Cerhan, James R ^h   Link, Brian K ⁱ   Zelenetz, Andrew D ^e   Friedberg, Jonathan W ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c GENENTECH INC   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

^e Carol G Simon Cancer Center ^*

^f EMORY UNIVERSITY   (United States)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REPRODUCIBILITY; SURVIVAL TIME; TREATMENT OUTCOME; VERY ELDERLY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EPIDEMIOLOGY; KAPLAN MEIER METHOD; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PREDNISONE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VINCRISTINE;

EID: 84940546789     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.7534     Document Type: Article

References (36)

1. Zelenetz AD, Abramson JS, Advani RH, et al: Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 9:484-560, 2011
2. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas MD Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006
3. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
4. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005
5. Tan D, Horning SJ, Hoppe RT, et al: Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: The Stanford University experience. Blood 122:981-987, 2013
6. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
7. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
8. Federico M, Luminari S, Dondi A, et al: R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 Trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506-1513, 2013
9. Flinn IW, van der Jagt R, Kahl BS, et al: Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood 123:2944-2952, 2014
10. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013
11. Press OW, Unger JM, Rimsza LM, et al: Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31:314-320, 2013
12. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51, 2011
13. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
14. Federico M, Bellei M, Marcheselli L, et al: Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555-4562, 2009
15. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma - The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
16. Smith SM: Dissecting follicular lymphoma: High versus low risk. Hematology Am Soc Hematol Educ Program 2013:561-567, 2013
17. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
18. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
19. Bachy E, Brice P, Delarue R, et al: Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: Effect of response quality on survival - a study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 28:822-829, 2010
20. van Oers MH, Tonnissen E, Van Glabbeke M, et al: BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: Results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 28:2246-2252, 2010
21. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the National LymphoCare Study. J Clin Oncol 27:1202-1208, 2009
22. Link BK, Maurer MJ, Nowakowski GS, et al: Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272-3278, 2013
23. Epanechnikov VA: Parametric estimation of a multivariate probability density. Theory Probab Appl 1:153-158, 1969
24. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
25. Sabloff M, Atkins HL, Bence-Bruckler I, et al: A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 13:956-964, 2007
26. Pettengell R, Schmitz N, Gisselbrecht C, et al: Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A prospective randomized trial from the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 31:1624-1630, 2013
27. Robinson SP, Canals C, Luang JJ, et al: The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: An analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 48:1409-1414, 2013
28. Le Gouill S, De Guibert S, Planche L, et al: Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 96:1128-1135, 2011
29. Saad ED, Buyse M: Overall survival: Patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol 30:1750-1754, 2012
30. Wildiers H, Mauer M, Pallis A, et al: End points and trial design in geriatric oncology research: A joint European organisation for research and treatment of cancer - Alliance for Clinical Trials in Oncology - International Society of Geriatric Oncology position article. J Clin Oncol 31:3711-3718, 2013
31. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
32. Paoletti X, Oba K, Bang YJ, et al: Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-analysis. J Natl Cancer Inst 105:1667-1670, 2013
33. Maurer MJ, Ghesquieres H, Jais JP, et al: Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32:1066-1073, 2014
34. Cheung KJ, Shah SP, Steidl C, et al: Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 113:137-148, 2009
35. O'Shea D, O'Riain C, Taylor C, et al: The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 112:3126-3129, 2008
36. LaCasce AS, Kho ME, Friedberg JW, et al: Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol 26:5107-5112, 2008